Bluebird Bio and Genethon Announce Manufacturing Research Collaboration Centered on Lentiviral Vectors for Gene Therapy

Published: Dec 14, 2010

CAMBRIDGE, Mass. & EVRY, France--(BUSINESS WIRE)--bluebird bio (formerly Genetix Pharmaceuticals Inc.), an emerging leader in the development of innovative gene therapies for severe genetic disorders, and Généthon, a leader in the field of gene therapy treatments for rare diseases, today announced a research collaboration focused on process development and scale up efforts for the manufacturing of lentiviral vectors. This agreement is designed to enable substantial advances in existing manufacturing process for the benefit of both partners. It will also strengthen bluebird bio’s manufacturing platform to enable robust, commercial-scale manufacturing and broaden the company’s capabilities in Europe. Specific terms of the agreement were not disclosed.

Back to news